Biotech firm PsiOxus Therapeutics, based at Milton Park, has launched the first clinical trial of its new anti-cancer vaccine, ColoAd1.

ColoAd1 is capable of destroying tumour cells at minute concentrations and can be injected into the bloodstream where it kills cancer cells while ignoring normal cells.

Chief executive John Beadle said: “This study could forge a path to a new treatment option for patients with metastatic cancer.”